Loading…
Gilead Sciences, Inc. is projected to rise to $163.55 by 2027, a +22% move from its current price of $133.69. GILD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $132.26 | $133.75 | $135.26 | +0.05% |
| May 30 | $131.71 | $133.81 | $135.95 | +0.09% |
| May 31 | $131.30 | $133.87 | $136.50 | +0.14% |
| Jun 1 | $130.96 | $133.94 | $136.98 | +0.18% |
| Jun 2 | $130.68 | $134.00 | $137.40 | +0.23% |
| Jun 3 | $130.42 | $134.06 | $137.79 | +0.28% |
| Jun 4 | $130.20 | $134.12 | $138.16 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $130.20 | $134.12 | $138.16 | +0.32% |
| Week 2 | $129.02 | $134.55 | $140.32 | +0.64% |
| Week 3 | $128.21 | $134.98 | $142.11 | +0.97% |
| Week 4 | $127.61 | $135.42 | $143.70 | +1.29% |
| Week 5 | $127.12 | $135.85 | $145.18 | +1.62% |
| Week 6 | $126.72 | $136.29 | $146.57 | +1.94% |
| Week 7 | $126.39 | $136.72 | $147.90 | +2.27% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases.
The company was incorporated in 1987 and is headquartered in Foster City, California.
Gilead Sciences, Inc. (GILD) is currently priced at $134.36 per share and has a market capitalization of $166.82B, ranking 88 by market cap. The stock sits in a position where the near-term forecast shows continued interest, with long-range upside suggested by the provided price-forecast figures.
A major floor 9.0% below — a decisive break under it would weaken the trend.
The nearest floor, 4.4% below — buyers have tended to step in here.
The nearest ceiling, 4.5% above — a clean break opens room to run.
A major ceiling 16.5% above — clearing it would confirm fresh momentum.
Key GILD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GILD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $132.59 | Buy | $132.92 | Buy |
| MA 10 | $131.78 | Buy | $132.48 | Buy |
| MA 20 | $132.27 | Buy | $132.78 | Buy |
| MA 50 | $135.40 | Sell | $134.88 | Sell |
| MA 100 | $137.88 | Sell | $134.39 | Sell |
| MA 200 | $128.50 | Buy | $128.66 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.02 | Neutral |
| Stoch RSI (14) | 86.80 | Sell |
| CCI (20) | 55.27 | Neutral |
| Williams %R (14) | -23.32 | Info |
| MACD (12,26,9) | 0.50 | Buy |
| ROC (12) | 1.80 | Buy |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 76.68 | Neutral |
| TRIX (15) | -0.14 | Sell |
| Awesome (5,34) | -1.09 | Sell |
| Ultimate (7,14,28) | 67.42 | Neutral |
| Momentum (10) | -1.25 | Sell |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 134.20 | Sell |
| ADX (14) | 13.44 | Neutral |
| ATR (14) | 1.36 | Info |
The 30-day technical picture shows bullish sentiment. RSI14 is 50, and the stock trades near the SMA50 of $135.86, above the SMA200 of $128.32. The near-term support is at $127.75 and resistance at $140.45, with a 30-day trading range from $124.24 to $145.30.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $118.30 | $133.69 | $175.07 | 0% | Neutral | |
| $133.61 | $163.55 | $209.56 | +22% | Bullish | |
| $150.51 | $187.60 | $246.65 | +40% | Bullish | |
| $173.52 | $219.55 | $294.67 | +64% | Bullish | |
| $213.25 | $273.43 | $373.47 | +105% | Bullish | |
| $233.79 | $303.38 | $420.84 | +127% | Bullish | |
| $253.43 | $332.54 | $467.78 | +149% | Bullish | |
| $277.68 | $368.18 | $524.55 | +175% | Bullish | |
| $287.77 | $385.33 | $555.48 | +188% | Bullish | |
| $307.82 | $416.06 | $606.40 | +211% | Bullish | |
| $489.84 | $690.42 | $1,054.21 | +416% | Bullish | |
| $882.26 | $1,333.46 | $2,181.89 | +897% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $118.30 | $133.69 | $156.23 | +0.00% |
| June 2026 | $116.07 | $135.40 | $161.01 | +1.28% |
| July 2026 | $118.80 | $139.39 | $167.33 | +2.95% |
| August 2026 | $118.32 | $139.44 | $168.61 | +0.04% |
| September 2026 | $117.68 | $139.21 | $169.33 | -0.16% |
| October 2026 | $120.31 | $142.81 | $174.64 | +2.58% |
| November 2026 | $121.30 | $144.41 | $177.43 | +1.12% |
| December 2026 | $118.81 | $141.85 | $175.07 | -1.77% |
Click any year to see its month-by-month GILD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, GILD is projected to trade between $118.30 and $175.07, averaging $133.69 — a potential gain of 0% from today's $133.69. A consolidation phase looks the most probable path here.
Gilead Sciences, Inc.'s 2027 outlook centres on $163.55, within a $133.61 to $209.56 range. That is up +22% on the projected 2026 average. That marks a +22% change versus current levels. Momentum favours further upside here.
By 2028, GILD could reach as high as $246.65, with a base case around $187.60 and support toward $150.51 — roughly +40% from $133.69. Buyers look set to stay in control over this stretch.
Expect GILD to range from $173.52 to $294.67 through 2029. The $219.55 average target implies a +64% move from current prices. That is up +17% on the projected 2028 average. Momentum favours further upside here.
The GILD price prediction for 2030 points to an average of $273.43 (low $213.25, high $373.47) — a potential gain of +105% on today's $133.69. Buyers look set to stay in control over this stretch.
In 2031, GILD is projected to trade between $233.79 and $420.84, averaging $303.38 — a potential gain of +127% from today's $133.69. That is up +11% on the projected 2030 average. Momentum favours further upside here.
Gilead Sciences, Inc.'s 2032 outlook centres on $332.54, within a $253.43 to $467.78 range. That is up +10% on the projected 2031 average. That marks a +149% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, GILD could reach as high as $524.55, with a base case around $368.18 and support toward $277.68 — roughly +175% from $133.69. Momentum favours further upside here.
Expect GILD to range from $287.77 to $555.48 through 2034. The $385.33 average target implies a +188% move from current prices. That is up +5% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The GILD price prediction for 2035 points to an average of $416.06 (low $307.82, high $606.40) — a potential gain of +211% on today's $133.69. Momentum favours further upside here.
In 2040, GILD is projected to trade between $489.84 and $1,054.21, averaging $690.42 — a potential gain of +416% from today's $133.69. That is up +66% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Gilead Sciences, Inc.'s 2050 outlook centres on $1,333.46, within a $882.26 to $2,181.89 range. That is up +93% on the projected 2040 average. That marks a +897% change versus current levels. Momentum favours further upside here.
Investing $1,000 in GILD today (≈ 7.479991 GILD) could be worth
$9,974.23
+$8,974.23 (+897%) by 2050 · US Dollar
Based on the average projected GILD price of $1,333.46 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GILDwould be worth at today's price.
$1,000 invested in GILD on May 27, 2025 (≈ 9.166743 GILD) would be worth
$1,225.5
+$225.5 (+22.6%) today · 1.23× · US Dollar
Based on a GILD entry price of $109.09 vs. today's $133.69.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $130.69 | $1,022.96 | +2.3% |
| 1 month ago | $127.75 | $1,046.5 | +4.6% |
| 3 months ago | $143.77 | $929.89 | -7.0% |
| 6 months ago | $125.84 | $1,062.38 | +6.2% |
| 1 year ago | $109.09 | $1,225.5 | +22.6% |
| All time (5.0y) ago | $65.32 | $2,046.69 | +104.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GILD forecast.
Our base-case forecast reaches $270.00 around 2030.
Implied market cap at $270.00: $335.22B
The multi-year forecast points to meaningful upside. In 2026 the avg price is $134.36 with a min of $118.30 and a max of $175.72 and a neutral sentiment. By 2030 the avg rises to $276.46 with a max of $377.70 and a min of $215.59, yielding an ROI of 105.8% and a bullish tone.
The forecast continues to show bullish momentum through 2040, where the avg is $695.08 and the ROI is 417.3%, and into 2050 with an avg of $1,343.62 and a ROI of 900%. The 2040 and 2050 figures imply substantial long-term appreciation, though these are estimates and carry uncertainty.
Tap a question to reveal the answer.
The 2030 average price is $276.46 with a max of $377.70 and a min of $215.59, and the forecast shows an ROI of 105.8%.
The forecast shows bullish sentiment from 2027 onward, with 2027 avg $165.21 (ROI 23%), 2028 avg $189.23 (ROI 40.8%), 2029 avg $220.91 (ROI 64.4%), and 2030+ bullish outlooks including an avg of $276.46 (ROI 105.8%). Note that these are estimates and not guarantees.
Yes. The 2050 forecast max is $2,198.70, with an avg of $1,343.62 and a 900% ROI.
Sentiment is bullish. RSI14 is 50; SMA50 is $135.86; SMA200 is $128.32. Support is at $127.75 and resistance at $140.45. The 30-day range is from $124.24 to $145.30.
Current price is $134.36 per share and market capitalization is $166.82B.
Gilead Sciences, Inc. Community Discussion
0Share your Gilead Sciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.